Syquant Capital Sas Spring Works Therapeutics, Inc. Call Options Transaction History
Syquant Capital Sas
- $302 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SWTX
# of Institutions
358Shares Held
63.2MCall Options Held
5.81MPut Options Held
2.55M-
Vanguard Group Inc Valley Forge, PA7.08MShares$333 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$264 Million0.0% of portfolio
-
State Street Corp Boston, MA2.92MShares$137 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.58MShares$121 Million0.01% of portfolio
-
Woodline Partners LP San Francisco, CA2.14MShares$101 Million0.66% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.93B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...